The coronavirus, SARS-CoV-2, outbreak has highlighted the need for rapid vaccine development. This complex task requires a high throughput, standardized and reliable screening tool to qualify potential candidates and to ensure quality control.
The automated LabChip® GXII Touch™ protein and nucleic acid characterization system supports rapid, reliable and quantitative protein and nucleic acid analysis. The LabChip® platform supports SARS-CoV-2 vaccine development through the analysis of protein source material used in several technologies under evaluation as potential SARS-CoV-2 vaccines, including nucleic acid and protein subunit strategies.